Cognition in schizophrenia - A systematic review

Drug Discovery Today: Therapeutic Strategies

Volumn 8, Issue 1-2, 2011, Pages 43-48

  Nielsen, René Ernst ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Regional Psychiatric Services West Central Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE;

CANNABIS ADDICTION; CIGARETTE SMOKING; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; CONVULSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; GENETICS; HUMAN; NEUROBIOLOGY; PSYCHOLOGIC TEST; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 84862122078     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2011.09.004     Document Type: Review

References (40)

1. Messias, E.L. et al. (2007) Epidemiology of schizophrenia: review of findings and myths. Psychiatr. Clin. N. Am. 30, 323-338 (Pubitemid 47299146)
2. Green, M.F. et al. (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr. Bull. 26, 119-136 (Pubitemid 30317696)
3. Szoke, A. et al. (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. Br. J. Psychiatry 192, 248-257 (Pubitemid 351692396)
4. Rund, B.R. (2009) Is schizophrenia a neurodegenerative disorder? Nord. J. Psychiatry 63, 196-201
5. Need, A.C. et al. (2009) A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum. Mol. Genet. 18, 4650-4661
6. Chen, L.S. et al. (2009) Familial aggregation of clinical and neurocognitive features in sibling pairs with and without schizophrenia. Schizophr. Res. 111, 159-166
7. Minzenberg, M.J. et al. (2009) Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 66, 811-822
8. Buchanan, R.W. et al. (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31, 5-19 (Pubitemid 41214353)
9. Gonzalez-Blanch, C. et al. (2010) First-episode schizophrenia patients neuropsychologically within the normal limits: evidence of deterioration in speed of processing. Schizophr. Res. 119, 18-26
10. Keefe, R.S. et al. (2005) Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry 57, 688-691 (Pubitemid 40409709)
11. Caspi, A. et al. (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr. Res. 65, 87-94 (Pubitemid 37434015)
12. Osler, M. et al. (2007) Cognitive function in childhood and early adulthood and hospital admission for schizophrenia and bipolar disorders in Danish men born in 1953. Schizophr. Res. 92, 132-141 (Pubitemid 46561225)
13. Kyriakopoulos, M. and Frangou, S. (2007) Pathophysiology of early onset schizophrenia. Int. Rev. Psychiatry 19, 315-324 (Pubitemid 47206978)
14. Rajji, T.K. et al. (2009) Age at onset and cognition in schizophrenia: metaanalysis. Br. J. Psychiatry 195, 286-293
15. Green, M.F. et al. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301-307 (Pubitemid 39164514)
16. Buchanan, R.W. et al. (2010) The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr. Bull. 10.1093/schbul/sbq038
17. Levaux, M.N. et al. (2007) Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur. Psychiatry 22, 104-115
18. Fett, A.K. et al. (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 35, 573-588
19. Harvey, P.D. (2007) Will improving cognition change functional outcomes in schizophrenia? Psychiatry (Edgmont.) 4, 58-60
20. Wykes, T. et al. (2011) A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 168, 472-485
21. Johansen, R. et al. (2011) Cognitive and clinical factors are associated with service engagement in early-phase schizophrenia spectrum disorders. J. Nerv. Ment. Dis. 199, 176-182
22. Dominguez, Mde.G. et al. (2009) Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations Psychol. Bull. 135, 157-171
23. Ventura, J. et al. (2010) Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr. Res. 121, 1-14
24. Hill, S.K. et al. (2010) Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev. Neurother. 10, 43-57
25. Minzenberg, M.J. et al. (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 161, 116-124 (Pubitemid 38419316)
26. Davidson, M. et al. (2009) Cognitive effects of antipsychotic drugs in firstepisode schizophrenia and schizophreniform disorder: a Randomized, Open-Label Clinical Trial (EUFEST). Am. J. Psychiatry 166, 675-682
27. Keefe, R.S. et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633-647 (Pubitemid 46878665)
28. Kontis, D. et al. (2010) Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 1333-1341
29. Kawai, N. et al. (2006) High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1009-1014 (Pubitemid 43928208)
30. Vares, M. et al. (2011) Concomitant medication of psychoses in a lifetime perspective. Hum. Psychopharmacol. 10.1002/hup.1209 Epub.
31. Barker, M.J. et al. (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch. Clin. Neuropsychol. 19, 437-454 (Pubitemid 38373546)
32. Singh, S.P. et al. (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 197, 174-179
33. Nielsen, J. et al. (2011) Optimizing clozapine treatment. Acta Psychiatr. Scand. 123, 411-422
34. Roepke, S. et al. (2011) Stimulus pulse-frequency-dependent efficacy and cognitive adverse effects of ultrabrief-pulse electroconvulsive therapy in patients with major depression. J. ECT 27, 109-113
35. Rami, L. et al. (2004) Absence of additional cognitive impairment in schizophrenia patients during maintenance electroconvulsive therapy. Schizophr. Bull. 30, 185-189 (Pubitemid 38568795)
36. Goldberg, J.F. and Burdick, K.E. (2001) Cognitive side effects of anticonvulsants. J. Clin. Psychiatry 62 (Suppl. 14), 27-33 (Pubitemid 32591415)
37. Winterer, G. (2010) Why do patients with schizophrenia smoke? Curr. Opin. Psychiatry 23, 112-119
38. Nielsen, R.E. and Nielsen, J. (2009) Antipsychotic drug treatment for patients with schizophrenia. Clin. Med.: Ther. 1, 1053-1068
39. Rabin, R.A. et al. (2011) The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 128, 111-116
40. D'Souza, D.C. et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition. Psychosis Addict. Biol. Psychiatry 57, 594-608